Nervous System Symptoms Associated With COVID 19

Study Overview
=================
Brief Summary
-----------------
This study aim to prospectively evaluate the neuropsychiatric symptoms of patients infected with the SARS-CoV-2 virus by a standardized neuropsychiatric examination : the global CASE scale (Clinical Assessment Scale in Autoimmune Encephalitis), and the prevalence of disturbances of consciousness, focal neurological deficit, cognitive impairment, headache, anosmia, sleep disturbances, impaired autonomic nervous system and peritraumatic stress.

Official Title
-----------------
Nervous System Symptoms Associated With COVID 19 : NS-COV

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Other: NEURO +
* Other: NEURO -


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Being hospitalized at the Toulouse University Hospital for a COVID-19 infection proven by a probable PCR or COVID-type examination on the chest scan Have given oral consent for the collection of clinical neurological data Be in a clinical state compatible with a 30-minute neurological examination Be French-speaking Be affiliated to a Social Security scheme Exclusion Criteria: Refusal of the neurological examination History of neurological pathology at a severe stage Pregnant or breastfeeding woman Persons with tutors or curators

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Interventional Model Description: This is an observational, prospective, cross-sectional and monocentric cohort study
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: NEURO +<br>Patients neuro + are those with a CASE score ≥ 2, Neuro + patients will benefit from additional evaluations using paraclinical examinations | Other: NEURO +<br>* The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score : The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005) the Peri traumatic distress inventory (Jehel et al., 2005) and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004) Neuro + patients will also have a Brain MRI, cerebrospinal fluid analysis, EEG, as well as an ambulatory sleep recording and electromyography depending on the symptoms observed.<br>|
| Other: NEURO -<br>Patients neuro - are those with a CASE score < 2 | Other: NEURO -<br>* The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score : The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005) the Peri traumatic distress inventory (Jehel et al., 2005) and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage of patients in the Neuro + and Neuro- groups | The percentage is deducted from the score on a global scale by the Clinical Assessment Scale in Autoimmune Between 0 and 1, patients will be classified in the Neuro group, if this score is greater than or equal to 2, patients will be classified in the Neuro + group. | Baseline T0 : inclusion visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nervous system, coronavirus, SARS-CoV-2, Nervous system symptoms